GlycoVaxyn, a Switzerland-based developer of conjugated vaccines that target bacterial infections, has raised CHF 11.5 million ($9.3m) in Series A funding from seed backers Sofinnova Partners and Index Ventures. www.glaxovaxyn.com
GlycoVaxyn, a Switzerland-based developer of conjugated vaccines that target bacterial infections, has raised CHF 11.5 million ($9.3m) in Series A funding from seed backers Sofinnova Partners and Index Ventures. www.glaxovaxyn.com
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.